Candida isolates causing refractory or recurrent oropharyngeal candidiasis in 11 hospitals in China
暂无分享,去创建一个
F. Kong | Menglan Zhou | Yingchun Xu | M. Xiao | X. Hou | S. Chen | He Wang | Li Zhang | Shu-ying Yu | Ge Zhang | S. Duan | Jingjia Zhang | W. Kang
[1] U. Pennsylvania,et al. Clinical and Laboratory Standards Institute , 2019, Springer Reference Medizin.
[2] Y. Li,et al. Five-Year National Surveillance of Invasive Candidiasis: Species Distribution and Azole Susceptibility from the China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study , 2018, Journal of Clinical Microbiology.
[3] Jun Liu,et al. Epidemiology and antifungal susceptibilities of yeast isolates causing invasive infections across urban Beijing, China. , 2017, Future microbiology.
[4] R. Mouriño-Pérez,et al. Candida species diversity and antifungal susceptibility patterns in oral samples of HIV/AIDS patients in Baja California, Mexico , 2016, Medical mycology.
[5] A. Jayachandran,et al. Oral Candidiasis among Cancer Patients Attending a Tertiary Care Hospital in Chennai, South India: An Evaluation of Clinicomycological Association and Antifungal Susceptibility Pattern , 2016, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.
[6] P. Das,et al. Species distribution & antifungal susceptibility pattern of oropharyngeal Candida isolates from human immunodeficiency virus infected individuals , 2016, The Indian journal of medical research.
[7] H. Hua,et al. Efficacy and safety of miconazole for oral candidiasis: a systematic review and meta-analysis. , 2016, Oral diseases.
[8] B. Ataei,et al. Candidiasis in Pediatrics; Identification and In vitro Antifungal Susceptibility of the Clinical Isolates , 2016, Iranian journal of pediatric hematology and oncology.
[9] F. Kong,et al. A Comprehensive Evaluation of the Bruker Biotyper MS and Vitek MS Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry Systems for Identification of Yeasts, Part of the National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study, 2012 to 2013 , 2016, Journal of Clinical Microbiology.
[10] A. Bitew,et al. Spectrum and the In Vitro Antifungal Susceptibility Pattern of Yeast Isolates in Ethiopian HIV Patients with Oropharyngeal Candidiasis , 2016, International journal of microbiology.
[11] M. Pinteala,et al. Etiologic Agents and Antifungal Susceptibility of Oral Candidosis from Romanian patients with HIV-infection or type 1 diabetes mellitus , 2016, Polish journal of microbiology.
[12] W. Hryniewicz,et al. Usefulness of CHROMagar Candida Medium, Biochemical Methods – API ID32C and VITEK 2 Compact and Two MALDI-TOF MS Systems for Candida spp. Identification , 2016, Polish journal of microbiology.
[13] G. Kerbauy,et al. Oral Candida colonization in HIV-infected patients in Londrina-PR, Brazil: antifungal susceptibility and virulence factors. , 2015, Journal of infection in developing countries.
[14] Xuelin Han,et al. Occurrence of oral Candida colonization and its risk factors among patients with malignancies in China , 2015, Clinical Oral Investigations.
[15] A. Berbéri,et al. Epidemiology of Oropharyngeal Candidiasis in Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Patients and CD4+ Counts , 2015, Journal of international oral health : JIOH.
[16] L. Soares,et al. Effect of the crude extract of Eugenia uniflora in morphogenesis and secretion of hydrolytic enzymes in Candida albicans from the oral cavity of kidney transplant recipients , 2015, BMC Complementary and Alternative Medicine.
[17] J. Bagan,et al. Current treatment of oral candidiasis: A literature review , 2014, Journal of clinical and experimental dentistry.
[18] P. Hsueh,et al. Comparison of the Accuracy of Two Conventional Phenotypic Methods and Two MALDI-TOF MS Systems with That of DNA Sequencing Analysis for Correctly Identifying Clinically Encountered Yeasts , 2014, PloS one.
[19] A. Amani,et al. Species distribution and antifungal susceptibility of Candida spp. isolated from superficial candidiasis in outpatients in Iran. , 2014, Journal de mycologie medicale.
[20] Jianping Xu,et al. Prevalent Drug Resistance Among Oral Yeasts from Asymptomatic Patients in Hainan, China , 2014, Mycopathologia.
[21] E. Presterl,et al. In Vitro Susceptibility of Candida Isolates from Organ Transplant Recipients to Newer Antifungals , 2014, Mycopathologia.
[22] Ryoichi Sakamoto,et al. Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006–2007 and 2012–2013 , 2014, BMC oral health.
[23] F. Kong,et al. Yeast Identification Algorithm Based on Use of the Vitek MS System Selectively Supplemented with Ribosomal DNA Sequencing: Proposal of a Reference Assay for Invasive Fungal Surveillance Programs in China , 2013, Journal of Clinical Microbiology.
[24] K. Rossem,et al. A Prospective Two‐Year Assessment of Miconazole Resistance in Candida Spp. with Repeated Treatment with 0.25% Miconazole Nitrate Ointment in Neonates and Infants with Moderate to Severe Diaper Dermatitis Complicated by Cutaneous Candidiasis , 2013, Pediatric dermatology.
[25] Yong-Gang Yao,et al. Asymptomatic oral yeast carriage and antifungal susceptibility profile of HIV-infected patients in Kunming, Yunnan Province of China , 2013, BMC Infectious Diseases.
[26] T. Calandra,et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[27] M. Pfaller,et al. Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012 , 2012, Journal of Clinical Microbiology.
[28] G. Quindós,et al. In Vitro Activities of New Triazole Antifungal Agents, Posaconazole and Voriconazole, Against Oral Candida Isolates from Patients Suffering from Denture Stomatitis , 2011, Mycopathologia.
[29] C. Koga‐Ito,et al. In vitro antifungal susceptibility of Candida spp. oral isolates from HIV-positive patients and control individuals. , 2011, Brazilian oral research.
[30] A. Rodloff,et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion , 2010, Journal of Clinical Microbiology.
[31] M. Moshi,et al. Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis , 2008, BMC Microbiology.
[32] W. Coulter,et al. In vitro susceptibility of oral Candida to seven antifungal agents. , 2005, Oral microbiology and immunology.
[33] P. Wayne. Reference method for broth dilution antifungal susceptibility testing of yeasts, Approved standard-second edition , 2002 .
[34] P. Connolly,et al. Does Long-Term Itraconazole Prophylaxis Result in In Vitro Azole Resistance in Mucosal Candida albicans Isolates from Persons with Advanced Human Immunodeficiency Virus Infection? , 2000, Antimicrobial Agents and Chemotherapy.
[35] B. Gazzard,et al. Unresponsive HIV-related oro-oesophageal candidosis--an evaluation of two new in-vitro azole susceptibility tests. , 1997, The Journal of antimicrobial chemotherapy.